Mural Oncology provides update on ARTISTRY-7 at Investor Day
PremiumThe FlyMural Oncology provides update on ARTISTRY-7 at Investor Day
2M ago
Mural Oncology provides update on ARTISTRY-6 cohort 2 at Investor Day
Premium
The Fly
Mural Oncology provides update on ARTISTRY-6 cohort 2 at Investor Day
2M ago
Mural Oncology plans to nominate candidate for IL-18 program by year-end
Premium
The Fly
Mural Oncology plans to nominate candidate for IL-18 program by year-end
2M ago
Mural Oncology reports Q2 EPS ($1.86) vs ($3.01) last year
PremiumThe FlyMural Oncology reports Q2 EPS ($1.86) vs ($3.01) last year
3M ago
Premium
Pre-Earnings
MURA Earnings this Week: How Will it Perform?
3M ago
Premium
Company Announcements
Mural Oncology Welcomes George Golumbeski as Director
3M ago
Mural Oncology expects cash to fund operations into Q4 of 2025
PremiumThe FlyMural Oncology expects cash to fund operations into Q4 of 2025
6M ago
Mural Oncology reports Q1 EPS ($1.84) vs ($2.78) last year
Premium
The Fly
Mural Oncology reports Q1 EPS ($1.84) vs ($2.78) last year
6M ago
Mural Oncology data for  IL-18 and IL-12 programs presented at AACR
Premium
The Fly
Mural Oncology data for IL-18 and IL-12 programs presented at AACR
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100